Dare Bioscience (DARE) Research & Development (2013 - 2026)

Dare Bioscience (DARE) has reported Research & Development for 14 consecutive years, with $241966.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 83.06% year-over-year to $241966.0; the trailing twelve-month figure through Jun 2026 stood at $3.5 million (down 64.41% YoY), and the FY2025 full-year result was $5.5 million, down 61.39% from the prior year.
• Research & Development retreated to $241966.0 in Q2 2026 per DARE's latest filing, from $622041.0 in the prior quarter.
• Across five years, Research & Development topped out at $13.0 million in Q4 2022 and bottomed at $241966.0 in Q2 2026.
• Historically, Research & Development has averaged $4.2 million across 5 years, with a median of $3.8 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Research & Development jumped 82.35% in 2022, then slumped 83.06% in 2026.
• Over 5 years, Research & Development stood at $13.0 million in 2022, then slumped by 70.72% to $3.8 million in 2023, then declined by 12.2% to $3.3 million in 2024, then plunged by 81.35% to $622041.0 in 2025, then slumped by 61.1% to $241966.0 in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $241966.0, $622041.0, and $1.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.